Precigen actobio announces additional positive interim data from phase 1b/2a study of ag019 actobiotics™, a novel therapy designed to address the underlying cause of type 1 diabetes

Germantown, md., oct. 1, 2021 /prnewswire/ -- precigen actobio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of precigen, inc. (nasdaq: pgen), today announced additional positive interim data from the ongoing phase 1b/2a clinical study investigating ag019 actobiotics™ for the treatment of recent-onset type 1 diabetes (t1d) (clinical trial identifier: nct03751007, eudract 2017-002871-24).
PGEN Ratings Summary
PGEN Quant Ranking